2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR

FGFR

Fibroblast growth factor receptor

FGFR

Related Products

PDF 1.46 MB

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0183S4
    Formononetin-d3-1
    		Inhibitor 99.67%
    Formononetin-d3-1 is the deuterium-labeled Formononetin (HY-N0183).
    Formononetin-d<sub>3</sub>-1
  • HY-112345
    PD-089828
    		Inhibitor 98.07%
    PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity.
    PD-089828
  • HY-108860
    Oncaspar
    		Agonist ≥99.0%
    Oncaspar (PEG-L-asparaginase; Pegasparaginase), a pegylated form of native Escherichia coli-derived L-asparaginase, breaks down the amino acid asparagine that are circulating in the bloodstream. Oncaspar plays an important role in acute lymphoblastic leukemia (ALL) through asparagine hydrolysis and activation of the integrated stress response (ISR) pathway.
    Oncaspar
  • HY-10517A
    (Z)-Orantinib
    		Inhibitor 99.44%
    (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/VEGFR2/KDR/Flk-1, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    (Z)-Orantinib
  • HY-156672
    S6K2-IN-1
    		Inhibitor 98.75%
    S6K2-IN-1 (Compound 2) is a S6K2 inhibitor (IC50: 22 nM). S6K2-IN-1 also inhibits FGFR4 (IC50: 216 nM). S6K2-IN-1 has acceptable stability in mouse liver microsomes.
    S6K2-IN-1
  • HY-145230
    FGFR2-IN-1
    		Inhibitor 99.78%
    FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC50 of 140 nM.
    FGFR2-IN-1
  • HY-163705
    BR-cpd7
    		Degrader 98.01%
    BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC50 of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717))
    BR-cpd7
  • HY-50904S1
    Nintedanib-13C,d3
    		Inhibitor ≥99.0%
    Nintedanib-13C,d3 is the 13C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/Flt-1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib-<sup>13</sup>C,d<sub>3</sub>
  • HY-160124
    Infigratinib-Boc
    		Inhibitor 98.29%
    Infigratinib-Boc is a derivative of Infigratinib containing a Boc (t-Butyloxy carbonyl) group. Infigratinib is an ATP-competitive pan-FGFR inhibitor.
    Infigratinib-Boc
  • HY-136849
    TL13-68
    		Inhibitor 98.88%
    TL13-68 is a biotin-tagged version of SM1-71, and it can be used to research the mechanism of SM1-71.
    TL13-68
  • HY-12965
    S49076
    		Inhibitor 99.44%
    S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
    S49076
  • HY-50904S2
    Nintedanib-d8
    		Inhibitor 99.90%
    Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/Flt-1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib-d<sub>8</sub>
  • HY-P99823
    Recifercept
    Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia.
    Recifercept
  • HY-100315
    XL 999
    		Inhibitor 99.01%
    XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for VEGFR2/KDR/Flk-1, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer.
    XL 999
  • HY-10981S
    Lenvatinib-d4
    		Inhibitor 99.59%
    Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
    Lenvatinib-d<sub>4</sub>
  • HY-RS04918
    FGFR3 Human Pre-designed siRNA Set A
    		Inhibitor

    FGFR3 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    FGFR3 Human Pre-designed siRNA Set A
    FGFR3 Human Pre-designed siRNA Set A
  • HY-RS04911
    FGFR1 Human Pre-designed siRNA Set A
    		Inhibitor

    FGFR1 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    FGFR1 Human Pre-designed siRNA Set A
    FGFR1 Human Pre-designed siRNA Set A
  • HY-RS04912
    Fgfr1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Fgfr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fgfr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Fgfr1 Mouse Pre-designed siRNA Set A
    Fgfr1 Mouse Pre-designed siRNA Set A
  • HY-19981A
    Derazantinib Racemate
    		Inhibitor 99.38%
    Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.
    Derazantinib Racemate
  • HY-145723C
    MAX-40279 hemiadipate
    		Inhibitor 99.26%
    MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).
    MAX-40279 hemiadipate
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity